Blast Crisis Definition in Chronic Myeloid Leukemia
Blast crisis in chronic myeloid leukemia (CML) is defined as the presence of ≥20% blasts in peripheral blood or bone marrow, aligning with the 2022 WHO revised classification that eliminated the traditional ≥30% threshold and the concept of accelerated phase. 1
Current Diagnostic Criteria
The 2025 European LeukemiaNet recommendations adopted the WHO 2022 classification, which represents a fundamental shift in how we conceptualize CML progression 1. This change is based on compelling evidence that:
- CML is essentially a biphasic disease rather than triphasic, as genetic changes characteristic of blast crisis are rarely found in chronic phase but are present in what was previously called "accelerated phase" 1
- Patients with 20-30% blasts have outcomes more similar to those with >30% blasts than those with 10-20% blasts, suggesting they warrant more aggressive treatment including allogeneic stem cell transplantation when possible 1
- The diagnostic threshold now aligns with acute myeloid leukemia criteria (≥20% blasts), creating consistency across chronic myeloid neoplasms 1
Historical Context and Controversy
The longstanding Karanas and Silver definition used ≥30% blasts 1, which was also adopted by NCCN guidelines 2. However, the 2025 ELN recommendations explicitly moved away from this traditional three-phase model (chronic, accelerated, blast) in favor of recognizing CML as biphasic 1.
This change is controversial but scientifically justified. The arbitrary blast percentage cutoffs are less acceptable in the modern genomics era, and gene expression profiling demonstrates that the bulk of genetic changes in progression occur during the transition from chronic phase to what was previously termed accelerated phase 2.
Clinical Implications
Blast crisis represents an oncologic emergency with significantly increased mortality primarily from infections and bleeding 3. Key features include:
- Presence of very immature cells as the predominant cell type in blood and marrow
- Morphologic spectrum similar to acute myeloid leukemia (myeloblasts, promyelocytes, immature monocytes, myelomonocytes, proerythroblasts, or immature megakaryocytes) 4
- Often accompanied by additional chromosomal abnormalities (up to 80% of cases) and multiple mutations 5
- Results from continued BCR-ABL activity leading to genetic instability, DNA damage, and impaired DNA repair 5
High-Risk Features to Monitor
The WHO classification recognizes that patients can present with high-risk features or develop changes predictive of impending disease progression 1. Watch for:
- High-risk additional chromosomal abnormalities (ACA) in Ph-positive cells, including major route abnormalities (+8, +Ph, i(17q), +19, +17, +21) or minor route abnormalities (−7/7q-, 11q23, 3q26.2) 1
- Complex aberrant karyotypes
- These warning signs in chronic phase should prompt consideration of treatment intensification
The ≥20% blast threshold is now the standard definition, representing a more biologically sound and clinically actionable criterion for identifying patients who require urgent, aggressive intervention including consideration for allogeneic stem cell transplantation. 1